vs
Side-by-side financial comparison of Autohome Inc. (ATHM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Autohome Inc. is the larger business by last-quarter revenue ($249.8M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). Autohome Inc. runs the higher net margin — 23.8% vs 1.6%, a 22.2% gap on every dollar of revenue. Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -0.6%).
Autohome Inc. is a leading online destination for automobile consumers in China. Through its websites and mobile apps, it provides professionally produced content, user-generated content, comprehensive vehicle listings, and a suite of services for dealers, automakers, and car buyers, including new and used car listings, financing, insurance, and online transactions.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ATHM vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $249.8M | $177.4M |
| Net Profit | $59.4M | $2.9M |
| Gross Margin | 63.7% | — |
| Operating Margin | 8.3% | 3.9% |
| Net Margin | 23.8% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | $249.8M | $179.5M | ||
| Q2 25 | $245.4M | $181.1M | ||
| Q1 25 | $244.3M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $252.9M | $168.6M | ||
| Q2 24 | $257.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $59.4M | $5.4M | ||
| Q2 25 | $56.0M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.0M | $-143.5M | ||
| Q2 24 | $69.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | 63.7% | 80.9% | ||
| Q2 25 | 71.4% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 77.0% | 76.9% | ||
| Q2 24 | 81.5% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 8.3% | 3.5% | ||
| Q2 25 | 16.9% | 4.7% | ||
| Q1 25 | 13.0% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 4.7% | -82.8% | ||
| Q2 24 | 22.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 23.8% | 3.0% | ||
| Q2 25 | 22.8% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.1% | -85.1% | ||
| Q2 24 | 26.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $653.9M |
| Total Assets | — | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | — | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | — | $749.6M | ||
| Q2 24 | — | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATHM
| Online marketplace and others | $114.7M | 46% |
| Leads generation services | $93.2M | 37% |
| Media services | $41.9M | 17% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
